Acromegaly

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, June 10, 2022
Financial compensation, Congenital adrenal hyperplasia, Acromegaly, Medication, Employment, Nasdaq, Therapy, Carcinoid syndrome, ACTH, SST2, GLOBE, Congenital hyperinsulinism, SAN, Degenerative disease, Drug discovery, Wilms' tumor, Pharmaceutical industry

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that onJune 10, 2022,the Compensation Committee of Crinetics Board of Directors granted non-qualified stock option awards to purchase an aggregate of 138,500 shares of its common stock to seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the 2021 Inducement Plan).

Key Points: 
  • SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that onJune 10, 2022,the Compensation Committee of Crinetics Board of Directors granted non-qualified stock option awards to purchase an aggregate of 138,500 shares of its common stock to seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the 2021 Inducement Plan).
  • The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Crinetics Presents Clinical and Research Results at ENDO 2022

Retrieved on: 
Wednesday, June 8, 2022
ENDO, Congenital adrenal hyperplasia, Acromegaly, Policy, PTH, HI, Medication, Nasdaq, Therapy, ACTH, Carcinoid syndrome, SST2, Endocrine system, Adrenocorticotropic hormone, GLOBE, Congenital hyperinsulinism, SAN, Degenerative disease, Drug discovery, Poster, Wilms' tumor, CAH, Hypercalcaemia, Pharmaceutical industry, Human

Results from the companys Phase 1 study of CRN04777, the companys investigational candidate for the treatment of congenital hyperinsulinism (HI) will be presented as a narrated Poster Plus.

Key Points: 
  • Results from the companys Phase 1 study of CRN04777, the companys investigational candidate for the treatment of congenital hyperinsulinism (HI) will be presented as a narrated Poster Plus.
  • For attendees of ENDO 2022, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#822) and in the virtual exhibit hall.
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
  • Paltusotine, a somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors.

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022

Retrieved on: 
Wednesday, June 8, 2022
ENDO, Hierarchy, Adult, Northwestern Health Sciences University, Disease, Octreotide, Maintenance, Neurosurgery, Endocrine system, FACE, 2021 Essex County Council election, Patient, Safety, GH, Union, Oregon Health & Science University, RCT, Oregon Health Plan, Degenerative disease, Pharmaceutical industry, Acromegaly

The conference will be held virtually and in person from June 11-14, 2022 in Atlanta, Georgia.

Key Points: 
  • The conference will be held virtually and in person from June 11-14, 2022 in Atlanta, Georgia.
  • The MPOWERED trial was a global, randomized, open-label and active-controlled, 15-month trial intended to support approval of Mycapssa in the European Union.
  • These patients were then followed for an additional nine months in the randomized controlled treatment (RCT) phase.
  • At the end of the RCT phase patients were provided the option to continue into an open label phase and receive Mycapssa.

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

Retrieved on: 
Tuesday, June 7, 2022
Congenital adrenal hyperplasia, Acromegaly, Investor, Medication, Therapy, Carcinoid syndrome, ACTH, Congenital hyperinsulinism, Degenerative disease, Drug discovery, Wilms' tumor, Event, Book, Pharmaceutical industry

In addition, the live and archived presentation will be accessible on the Events & Presentations page in the Investors section on the Companys website.

Key Points: 
  • In addition, the live and archived presentation will be accessible on the Events & Presentations page in the Investors section on the Companys website.
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
  • Currently, paltusotine is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors.
  • All of the companys drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

Retrieved on: 
Wednesday, June 1, 2022
Woman, Kidney, Osteoporosis, Biomarker, Șaeș, Acromegaly, Phosphorus, Urine, Parathyroid hormone, Standard of care, Failure, Half-life, Osteopenia, Blood, PTH, Â, Chronic kidney disease, Serum, Hypoparathyroidism, Patient, Endocrinology, GLOBE, Risk, Calcium, Quality of life, Union, Twitter, Population, Vitamin D, Tissue, Pharmaceutical industry, Dietary supplement, Medical imaging

This was the first cohort of an ongoing Phase 2a trial composed of two consecutive cohorts.

Key Points: 
  • This was the first cohort of an ongoing Phase 2a trial composed of two consecutive cohorts.
  • We look forward to the results from cohort 2 to further characterize dose-relationship and inform the design of our pivotal trial.
  • Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma, added, We are very pleased with the promising results from cohort 1 of this important study.
  • Clinical manifestations of hypoparathyroidism impact a large number of tissues and organ systems, and in particular, the kidneys and bone.

Posting of Annual Report and Notice of AGM

Retrieved on: 
Wednesday, June 1, 2022
Proxy, Lipodystrophy, Lists of diseases, EB, Acromegaly, EMA, European, Forward-looking statement, Environment, Octreotide, Investment, Lomitapide, Metreleptin, Shareholder, CHMP, FDA, Patient, COVID-19, Birth, Diet, AGM, GL, Dietary supplement, Pharmaceutical industry, Junctional epidermolysis bullosa (medicine), EU

Shareholders using the telephone facility should, therefore, also submit their Form of Proxy by the relevant deadline in advance of the AGM.

Key Points: 
  • Shareholders using the telephone facility should, therefore, also submit their Form of Proxy by the relevant deadline in advance of the AGM.
  • Amryt comprises a strong and growing portfolio of commercial and development assets.
  • Mycapssa has also been submitted to the EMA and is not yet approved in Europe.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

Retrieved on: 
Wednesday, May 25, 2022
Disease, U.S. Securities and Exchange Commission, Webcast, Pharmacokinetics, Adrenocorticotropic hormone, Androgen, Conference, Insulin resistance, Safety, Adrenal insufficiency, Mental health, Private Securities Litigation Reform Act, Drug discovery, Serum, Wilms' tumor, Pharmacology, Infertility, Blood pressure, Hirsutism, Woman, Pituitary gland, Carcinoid syndrome, Clinical trial, COVID-19, Research, SST2, ACTH, Man, Birth defect, GLOBE, Inflammation, MC2R, Company, Obesity, Congenital adrenal hyperplasia, HPA, Half-life, SAD, Trial of the century, MAD, CAH, FDA, Conference call, Therapy, Security (finance), ID, Degenerative disease, Neoplasm, Metabolism, Nasdaq, Patient, Acromegaly, Glucocorticoid, Intellectual property, Medication, Hyperinsulinism, Acne, Lists of diseases, Endocrinology, Hypertension, Pharmaceutical industry

SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced positive results from the multiple-ascending dose (MAD) portion of a first-in-human Phase 1 clinical study of CRN04894, the company's first-in-class, investigational, oral, nonpeptide adrenocorticotropic hormone (ACTH) antagonist that is being developed for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions of excess ACTH. Following administration of CRN04894, results showed serum cortisol below normal levels and a marked reduction in 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations.

Key Points: 
  • Safety and pharmacokinetic data were consistent with expectations from the single-ascending dose cohorts in the Phase 1 study.
  • Crinetics plans to present additional details of safety, efficacy, and biomarker results from the CRN04894 Phase 1 study at an endocrinology-focused medical meeting in 2022.
  • Crinetics will hold a conference call and live audio webcast today, May 25, 2022, at 8:00 a.m. Eastern Time to discuss results from the MAD cohorts of the Phase 1 study of CRN04894.
  • Participants were divided into multiple cohorts in the single ascending dose (n=39) and multiple ascending dose (n=49) portions of the study.

Amryt Announces Details of EMA Contingent Value Rights Payment

Retrieved on: 
Tuesday, May 17, 2022
Deed poll, USD, Loan note, CHMP, EMA, Diet, Lipodystrophy, EB, Investment, Degenerative disease, Birth, European, COVID-19, Lomitapide, Octreotide, Link group, GL, Acquisition, Company, Holder, European Medicines Agency, Deed, Lists of diseases, Somatostatin, Nasdaq, Environment, Patient, Acromegaly, Metreleptin, Forward-looking statement, Contingent value rights, Pharmaceutical industry, Security (finance), Dietary supplement, Junctional epidermolysis bullosa (medicine), EU

Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a Loan Note).

Key Points: 
  • Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a Loan Note).
  • The total amount due to each CVR Holder will be paid by cheque on the Payment Date.
  • Amryt alsointends to develop oral medications that are currently only available as injectable therapies through itsTransient PermeabilityEnhancer (TPE) technology platform.For more information on Amryt, including products, please visit www.amrytpharma.com .
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO

Retrieved on: 
Monday, May 16, 2022
Chronic kidney disease, Risk, Blood, Calcium, Urine, Parathyroid hormone, Adenoma, GH, Patient, Woman, Acromegaly, Half-life, Kidney, Research, PTH, SSAS, Hypoparathyroidism, Osteoporosis, Twitter, Endocrinology, Pharmaceutical industry

AZP-3813 was identified and optimized through a research collaboration with PeptiDream and is being developed as a potential next-generation GHRA therapeutic.

Key Points: 
  • AZP-3813 was identified and optimized through a research collaboration with PeptiDream and is being developed as a potential next-generation GHRA therapeutic.
  • Amolyt Pharma, a clinical stage biotechnology company, is building on its teams established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
  • Its development portfolio includes AZP-3601, a long-acting PTH analog as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
  • Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Congenital hyperinsulinism, Degenerative disease, Wilms' tumor, Research, Congenital adrenal hyperplasia, Annual report, Nasdaq, Director, Leadership, Patient, Investment, Form 10-K, Acromegaly, Carcinoid syndrome, Clinical trial, COVID-19, SAD, Marketing, Fasting, MAD, FDA, Efficiency, ACTH, SAN, Securities Exchange Act of 1934, SST2, Securities Act of 1933, Time, Intellectual property, Medication, Board, Biomarker, Insulin, Board of directors, Drug Quality and Security Act, Hyperinsulinism, Drug development, Therapy, SEC, Drug discovery, GLOBE, Pharmaceutical industry, Online gambling, Cryptocurrency

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2022.
  • Reported positive top-line results from multiple-ascending dose (MAD) cohorts of the CRN04777 Phase 1 study.
  • Crinetics plans to initiate a Phase 2 study of CRN04777 in congenital hyperinsulinism patients in the second half of 2022, following discussions with global regulators.
  • Additional information on risks facing Crinetics can be found under the heading Risk Factors in Crinetics periodic reports, including its annual report on Form 10-K for the year ended December 31, 2021.